FHI 360’s Control and Prevention of Tuberculosis (CAP-TB) project aims to reduce the incidence and mortality of multidrug-resistant TB (MDR-TB) in China, Laos, Myanmar (Burma), Papua New Guinea and Thailand. Under this project, FHI 360 partners with national TB programs and stakeholders to develop and implement a strategic model for MDR-TB management that will enable countries to move toward eliminating this disease. The project, funded by the U.S. Agency for International Development (USAID), serves as a regional leader for developing active drug safety systems to support patients who are on new TB drugs and regimens. This is a critical priority given the growing use of bedaquiline, the first new drug in more than 40 years that treats TB.
The CAP-TB model:
- Strengthens health systems by building expertise in MDR-TB management that is patient-centered and community-driven
- Changes traditional norms for patient-provider communication
- Uses social media to create virtual communities that support patients
- Develops technology that uses data to improve the management of patients with MDR-TB
The CAP-TB project was profiled in October 2016 at the 47th World Conference on Lung Health in Liverpool, United Kingdom, through the conference’s thought leadership series. This short film highlights CAP-TB’s work in Yunnan Province, China.
